January 5, 2018 / 2:08 PM / 7 months ago

BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

Jan 5 (Reuters) - Amgen Inc:

* FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA

* AMGEN INC - APPROVAL IS BASED ON DATA FROM PIVOTAL PHASE 3 ‘482 STUDY WHICH ENROLLED 1,718 PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below